SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gofman JW, Jones HB, Lindgren FT, Lyon TP, Elliott HA, Strisower B. Blood lipids and human atherosclerosis. Circulation 1950; 5: 16178.
  • 2
    Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II in atherosclerosis and related conditions. Am J Med 1951; 11: 48093.
  • 3
    Boyd GS. The estimation of serum lipoproteins: a micromethod based on zone electrophoresis and cholesterol estimations. Biochem J 1954; 58: 6805.
  • 4
    Oliver MF, Boyd GS. The plasma lipids in coronary artery disease. Br Heart J 1953; 15: 38741.
  • 5
    Cottet J, Mathivat A, Redel J. Therapeutic study of a synthetic hypocholesterolaemic agent: phenyl ethyl acetic acid. Presse Med 1954; 62: 93941.
  • 6
    Oliver MF, Boyd GS. Serum lipoprotein patterns in coronary sclerosis and associated conditions. Br Heart J 1955; 17: 299304.
  • 7
    Oliver MF. Reduction of serum lipid and uric acid levels by an orally active androsterone. Lancet 1962; i: 13213.
  • 8
    Thorp JM. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxyisobutyrate. Lancet 1962; i: 13236.
  • 9
    Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962; 194: 9489.
  • 10
    Oliver MF. Further observations on the effects of Atromid and ethyl chlorophenoxyisobutyrate on serum lipid levels. J Atheroscler Res 1963; 3: 42744.
  • 11
    Report of the Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069118.
  • 12
    Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; ii: 60060.
  • 13
    Dewar HA, Oliver MF. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J 1971; 4: 7846.
  • 14
    Oliver MF. Ischaemic heart disease: a secondary prevention trial using clofbrate. Br Med J 1971; 4: 77584.
  • 15
    Duncan LJP, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three year trial of Atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 45864.
  • 16
    Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991; 338: 152931.
  • 17
    Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, change in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 123745.
  • 18
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 3447.
  • 19
    Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3- methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolaemic activity. FEBS Lett 1976; 72: 3234.
  • 20
    Scandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 13839.
  • 21
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Study Group. N Engl J Med 1995; 333: 13017.
  • 22
    Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwindermann AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS). Circulation 1995; 91: 252840.
  • 23
    Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today 2006; 42: 3964.